21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Efectos del prazosin sobre el control de la presión arterial en hipertensos sometidos a diálisis

      research-article
      ,
      Cardiology
      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Se sometieron a tratamiento con prazosin 22 hipertensos en quienes se efectuaba hemodiálisis crónica. Ocho pacientes tenían hipertension sensible al volumen; 11, hipertension independiente del volumen, y 3, hipertension con renina alta. La presión arterial disminuyó en todos los pacientes con hipertension “volumen-sensible” desde la cifra anterior a la diálisis de 175 ± 5/100 ± 3, a 148 ± 4/75 ± 3 mmHg [p < 0.001) después de 3 meses de tratamiento. El prazosin solo fue eficaz en los enfermos “volumen-sensibles” en dosis de 5 ± 1 mg/día. La presión arterial disminuyó en los pacientes de hipertension “volumen-independiente” de 192 ± 7/105 ± 2 mmHg en la etapa de prediálisis, a 155 ± 6/80 ± 3 después de 3 meses (p < 0.001). Dos se controlaron valiéndose exclusiva-mente de prazosin en dosis de 12 ± 2 mg diarios. En 9 se necesitaron 27 ± 5 mg de prazosin al día y tratamiento antihipertensivo adicional. La presión arterial disminuyó de 183 ± 3/109 ± 6 mmHg en la prediálisis, a 173 ± 17/85 ± 3 mmHg en pacientes con renina alta, después de 3 meses. En un sujeto se logró control con 40 mg de prazosin al día. Dos necesitaron 40 mg de prazosin diarios y medicamento antihipertensivo adicional. Once sujetos señalaron mareos pasajeros en el primer mes de tratamiento. Una persona tuvo síncope recurrente que obligó a suprimir el prazosin. El prazosin es un antihipertensivo eficaz que puede utilizarse solo o combinado en todos los hipertensos sometidos a diálisis, con efectos secundarios mínimos.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-1557-3
          978-3-318-01519-5
          0008-6312
          1421-9751
          1980
          1980
          07 November 2008
          : 66
          : Suppl 2
          : 39-50
          Affiliations
          The Chromalloy American Kidney Center y División Renal, Departamento de Medicina, Escuela de Medicina, Universidad de Washington, St. Louis, Missouri, E.U.A.
          Article
          172998 Cardiology 1980;66:39–50
          10.1159/000172998
          7026031
          3a055a1e-59e3-441d-a394-e4f459b1a3c2
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 12
          Categories
          Prazosin en Hipertensión Arterial I

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          General medicine, Neurology, Cardiovascular Medicine, Internal medicine, Nephrology

          Comments

          Comment on this article